Why certain brain cells are more vulnerable in Huntington’s disease
Molecular Mechanisms Underlying Cell Type-Specific Vulnerability in Huntington’s Disease
This work looks at why some types of brain cells are more likely to be harmed in Huntington’s disease using patient tissue and advanced lab methods.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11325873 on NIH RePORTER |
What this research studies
Researchers at MIT are trying to find why only certain neurons die in Huntington’s disease by examining gene activity and immune signals in specific cell types. They use a method called TRAP to read RNA from particular cell types, run genetic screens in living brains to test which genes cause harm, and analyze single-cell sequencing data from Huntington’s patient tissue. Combining these approaches helps the team move beyond simple correlations to identify causal drivers of cell vulnerability. The findings are meant to point to biological pathways that could be targeted to protect at-risk neurons.
Who could benefit from this research
Good fit: People with Huntington’s disease (or their families) willing to donate brain tissue, blood, or other samples for research are the most relevant participants for this work.
Not a fit: People without Huntington’s disease or those seeking immediate clinical treatments are unlikely to receive direct benefit from this basic-science project.
Why it matters
Potential benefit: This research may identify specific genes or immune pathways to target so new treatments could protect vulnerable brain cells in Huntington’s disease.
How similar studies have performed: Single-cell profiling and TRAP have previously revealed disease-related changes in patient brain tissue, while the in vivo genetic screening approach is newer and aims to test which genes actually cause problems.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Heiman, Myriam — Massachusetts Institute of Technology
- Study coordinator: Heiman, Myriam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.